Cost Of Revenue - Deciphera Pharmaceuticals Inc (F:D05) - Alpha Spread
D

Deciphera Pharmaceuticals Inc
F:D05

Watchlist Manager
Deciphera Pharmaceuticals Inc
F:D05
Watchlist
Price: 38.5 EUR 1.32% Market Closed
Market Cap: 3.2B EUR
Have any thoughts about
Deciphera Pharmaceuticals Inc?
Write Note

Deciphera Pharmaceuticals Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Deciphera Pharmaceuticals Inc
Cost of Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
D
Deciphera Pharmaceuticals Inc
F:D05
Cost of Revenue
-$5.3m
CAGR 3-Years
-128%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cost of Revenue
-$18.3B
CAGR 3-Years
0%
CAGR 5-Years
-20%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Cost of Revenue
-$6.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Cost of Revenue
-$11.4B
CAGR 3-Years
-22%
CAGR 5-Years
-22%
CAGR 10-Years
-12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cost of Revenue
-$1.4B
CAGR 3-Years
-20%
CAGR 5-Years
-25%
CAGR 10-Years
-33%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cost of Revenue
-$1.8B
CAGR 3-Years
-3%
CAGR 5-Years
-26%
CAGR 10-Years
-26%

See Also

What is Deciphera Pharmaceuticals Inc's Cost of Revenue?
Cost of Revenue
-5.3m USD

Based on the financial report for Mar 31, 2024, Deciphera Pharmaceuticals Inc's Cost of Revenue amounts to -5.3m USD.

What is Deciphera Pharmaceuticals Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-128%

Over the last year, the Cost of Revenue growth was 40%. The average annual Cost of Revenue growth rates for Deciphera Pharmaceuticals Inc have been -128% over the past three years .

Back to Top